Caisse DE Depot ET Placement DU Quebec Cuts Holdings in Cencora, Inc. (NYSE:COR)

Caisse DE Depot ET Placement DU Quebec trimmed its holdings in Cencora, Inc. (NYSE:COR - Free Report) by 27.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 304,064 shares of the company's stock after selling 116,241 shares during the quarter. Caisse DE Depot ET Placement DU Quebec owned 0.16% of Cencora worth $68,317,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in COR. Price T Rowe Associates Inc. MD grew its holdings in Cencora by 0.9% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 8,859,452 shares of the company's stock worth $1,990,542,000 after acquiring an additional 78,066 shares during the last quarter. Boston Partners grew its stake in Cencora by 2.6% in the fourth quarter. Boston Partners now owns 5,007,100 shares of the company's stock valued at $1,128,058,000 after purchasing an additional 125,611 shares in the last quarter. Geode Capital Management LLC increased its holdings in Cencora by 3.1% during the fourth quarter. Geode Capital Management LLC now owns 4,326,064 shares of the company's stock worth $969,471,000 after buying an additional 130,213 shares during the last quarter. Invesco Ltd. lifted its stake in Cencora by 20.4% in the 4th quarter. Invesco Ltd. now owns 3,243,531 shares of the company's stock valued at $728,757,000 after purchasing an additional 550,246 shares during the last quarter. Finally, Northern Trust Corp boosted its stake in shares of Cencora by 11.6% during the 4th quarter. Northern Trust Corp now owns 2,421,237 shares of the company's stock worth $544,004,000 after acquiring an additional 252,028 shares during the period. 97.52% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CEO Robert P. Mauch sold 4,970 shares of Cencora stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $255.00, for a total transaction of $1,267,350.00. Following the sale, the chief executive officer now directly owns 51,070 shares in the company, valued at $13,022,850. The trade was a 8.87 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Silvana Battaglia sold 5,000 shares of Cencora stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the transaction, the executive vice president now directly owns 15,374 shares of the company's stock, valued at approximately $3,724,197.76. This trade represents a 24.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 50,223 shares of company stock worth $13,580,967. Corporate insiders own 10.80% of the company's stock.

Cencora Stock Performance

Shares of COR stock traded up $11.09 during trading on Wednesday, hitting $301.90. The company's stock had a trading volume of 1,115,492 shares, compared to its average volume of 1,684,960. The business has a fifty day moving average of $274.32 and a 200-day moving average of $252.29. The company has a market cap of $58.54 billion, a PE ratio of 42.94, a P/E/G ratio of 1.31 and a beta of 0.60. Cencora, Inc. has a 52 week low of $214.77 and a 52 week high of $309.35. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40.

Cencora (NYSE:COR - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $4.42 EPS for the quarter, topping the consensus estimate of $4.07 by $0.35. Cencora had a net margin of 0.46% and a return on equity of 328.62%. The business had revenue of $75.50 billion for the quarter, compared to analyst estimates of $75.41 billion. During the same quarter in the previous year, the firm posted $3.80 earnings per share. The company's revenue for the quarter was up 10.3% on a year-over-year basis. As a group, research analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. StockNews.com raised Cencora from a "hold" rating to a "buy" rating in a research report on Wednesday, March 12th. Evercore ISI upped their target price on Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a research report on Thursday, February 6th. Bank of America lifted their target price on shares of Cencora from $270.00 to $285.00 and gave the stock a "neutral" rating in a research report on Friday, April 11th. JPMorgan Chase & Co. raised their price target on shares of Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a report on Friday, January 24th. Finally, Morgan Stanley set a $288.00 target price on Cencora in a report on Tuesday, April 15th. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $290.00.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.